Childhood maltreatment has moderating influence on efficacy of psychotherapy

In the current issue of Psychotherapy and Psychosomatics, Klein and colleagues report the effect of childhood maltreatment on the outcome of psychotherapy. In the treatment of major depression, childhood maltreatment has been associated with an unfavorable outcome. One possible exception might be psychotherapy with the cognitive behavioral analysis system of psychotherapy (CBASP). CBASP is a treatment model that has been developed specifically for patients with persistent depressive disorder. CBASP targets specific maladaptive interpersonal behaviors that are associated with persistent depressive disorder and childhood maltreatment. We have therefore hypothesized that CBASP is more effective than supportive psychotherapy in patients retrospectively reporting childhood maltreatment.

The study compared the efficacy of Cognitive Behavioral Analysis System of Psychotherapy with nonspecific supportive psychotherapy in adult with early-onset chronic depression. Three quarters of the patients reported at least moderate to severe childhood maltreatment. The most common forms of childhood maltreatment were emotional neglect (65.5%) and emotional abuse (59.0%). Results show that CBASP was superior to supportive psychotherapy in the reduction of depressive symptoms. In addition, the presence of childhood maltreatment had a moderating influence on the efficacy of treatment. Specifically, emotional neglect was associated with a less favorable outcomes.

Based on the relevance of childhood maltreatment in chronic depression, CBASP might emerge as the treatment of choice for persistently depressed patients suffering from early interpersonal trauma.

Source: https://www.karger.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients